We are live on ! Find out more
SGA

Sector Gamma AS Portfolio holdings

AUM $423M
1-Year Est. Return 17.56%
This Fund
S&P 500
This Quarter Est. Return
+0.13%
1 Year Est. Return
+17.56%
3 Year Est. Return
+28.73%
5 Year Est. Return
+52.48%
10 Year Est. Return
+238.19%
AUM
$460M
AUM Growth
+$34.8M
Cap. Flow
+$33.8M
Cap. Flow %
7.34%
Top 10 Hldgs %
55.73%
Holding
42
New
9
Increased
17
Reduced
14
Closed
2

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$24.6M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$9.03M
3
ZBH icon
Zimmer Biomet
ZBH
+$7.81M
4
AZN icon
AstraZeneca
AZN
+$7.44M
5
BRKR icon
Bruker
BRKR
+$6.1M

Top Sells

Rank Stock Value
1
BDX icon
Becton Dickinson
BDX
+$13M
2
PFE icon
Pfizer
PFE
+$8.08M
3
LH icon
Labcorp
LH
+$7.34M
4
CAH icon
Cardinal Health
CAH
+$6.4M
5
BSX icon
Boston Scientific
BSX
+$4.52M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRK icon
1
Merck
MRK
$315B
$41M 8.9%
499,141
+23,337
+5% +$1.84M
GILD icon
2
Gilead Sciences
GILD
$167B
$40.5M 8.8%
681,538
+384,483
+129% +$24.6M
INCY icon
3
Incyte
INCY
$23.4B
$35.1M 7.63%
442,012
+63,160
+17% +$4.59M
BMY icon
4
Bristol-Myers Squibb
BMY
$124B
$24.4M 5.29%
333,558
-15,033
-4% -$1.01M
MDT icon
5
Medtronic
MDT
$106B
$22.9M 4.97%
206,006
+1,738
+0.9% +$184K
CAH icon
6
Cardinal Health
CAH
$53.5B
$21.4M 4.65%
377,270
-119,410
-24% -$6.4M
CVS icon
7
CVS Health
CVS
$137B
$20.1M 4.37%
198,873
-7,289
-4% -$766K
BSX icon
8
Boston Scientific
BSX
$65.4B
$17.5M 3.8%
395,335
-104,195
-21% -$4.52M
BIIB icon
9
Biogen
BIIB
$30.4B
$17.3M 3.75%
81,945
+15,346
+23% +$3.34M
CNC icon
10
Centene
CNC
$32.8B
$16.4M 3.56%
194,664
+11,518
+6% +$945K
BRKR icon
11
Bruker
BRKR
$8.86B
$16.2M 3.52%
251,952
+89,184
+55% +$6.1M
NUVA
12
DELISTED
NuVasive, Inc.
NUVA
$15.1M 3.28%
266,035
+25,344
+11% +$1.35M
ELV icon
13
Elevance Health
ELV
$80.9B
$14.3M 3.1%
29,018
-5,384
-16% -$2.46M
CI icon
14
Cigna
CI
$74.5B
$14M 3.04%
58,370
+16,870
+41% +$3.95M
OGN icon
15
Organon & Co
OGN
$3.55B
$11.9M 2.58%
339,738
-91,971
-21% -$3.15M
QGEN icon
16
Qiagen
QGEN
$8.49B
$10.7M 2.33%
206,742
+21,106
+11% +$1.09M
ALNY icon
17
Alnylam Pharmaceuticals
ALNY
$35.7B
$9.68M 2.1%
+59,251
New +$9.03M
ELAN icon
18
Elanco Animal Health
ELAN
$12.9B
$9.52M 2.07%
364,691
+19,461
+6% +$518K
ZBH icon
19
Zimmer Biomet
ZBH
$17.6B
$8.29M 1.8%
+64,801
New +$7.81M
AZN icon
20
AstraZeneca
AZN
$262B
$8.23M 1.79%
+62,000
New +$7.44M
BIO icon
21
Bio-Rad Laboratories Class A
BIO
$8.15B
$7.2M 1.56%
12,785
+1,146
+10% +$691K
IONS icon
22
Ionis Pharmaceuticals
IONS
$8.99B
$6.98M 1.52%
188,439
-21,098
-10% -$691K
BDX icon
23
Becton Dickinson
BDX
$43.6B
$6.98M 1.52%
26,889
-50,649
-65% -$13M
UHS icon
24
Universal Health Services
UHS
$9.15B
$6.88M 1.5%
47,467
+2,229
+5% +$308K
PFE icon
25
Pfizer
PFE
$143B
$6.72M 1.46%
129,738
-155,665
-55% -$8.08M
1
2

Similar funds

AFWM
AMJ Financial Wealth Management Leesburg, Virginia $424M AUM 37.24% 1-Year Est. Return
MP
McDonald Partners Cleveland, Ohio $424M AUM 29.07% 1-Year Est. Return
DS
Dalal Street West Lake Hills, Texas $423M AUM 115.19% 1-Year Est. Return
RS
Retirement Solution Redmond, Washington $423M AUM 16.83% 1-Year Est. Return
DF
Dunhill Financial London, United Kingdom $424M AUM 16.79% 1-Year Est. Return
OGM
OnyxPoint Global Management New York $424M AUM 84.95% 1-Year Est. Return
CPIM
Cypress Point Investment Management Mill Valley, California $424M AUM
MPPLM
Midwest Professional Planners Ltd (MPPL) Wausau, Wisconsin $425M AUM 28.89% 1-Year Est. Return

Sector Gamma AS's Q1 2022 Portfolio in Review

As of Q1 2022, Sector Gamma AS held 42 positions worth $460M, up 8.2% from $425M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Sector Gamma AS deployed $33.8M of net new capital in Q1 2022, opening 9 new positions and adding to 17 existing holdings. Its largest new stake was Alnylam Pharmaceuticals: 59,251 shares worth $9.68M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Becton Dickinson, an estimated $13M trimmed.

  • Sector Gamma AS's largest Q1 2022 buy was Alnylam Pharmaceuticals: 59,251 shares worth $9.68M.
  • Sector Gamma AS added most to Gilead Sciences in Q1 2022, an estimated $24.6M increase.
  • Sector Gamma AS's biggest Q1 2022 reduction was Becton Dickinson, cutting an estimated $13M.
  • Sector Gamma AS fully exited Labcorp in Q1 2022, selling an estimated $7.34M.
  • Sector Gamma AS's ten largest holdings make up 56% of its $460M portfolio in Q1 2022.
  • Sector Gamma AS opened 9 new positions and closed 2 in Q1 2022.
  • Sector Gamma AS's portfolio value rose 8.2% quarter-over-quarter to $460M.

Based on Sector Gamma AS's 13F filing for Q1 2022, filed 6 May 2022.